Evidence map›Paper›PMID 42130833›Full record

ArticleRSC advances2026

Design and optimization of a Cu-MOF@graphene oxide nanozyme for point-of-care colorimetric determination of sarcosine and H

Martin N Saad, Amr M Mahmoud, Sawsan M Amer, Ibrahim M El-Sherbiny, Hoda M Marzouk

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin N SaadPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University El-Kasr El-Aini Street 11562 Cairo Egypt martin.nady@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0003-1788-620X
Amr M MahmoudPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University El-Kasr El-Aini Street 11562 Cairo Egypt martin.nady@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0002-7804-6442
Sawsan M AmerPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University El-Kasr El-Aini Street 11562 Cairo Egypt martin.nady@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0002-4220-7478
Ibrahim M El-SherbinyNanomedicine Research Labs, Center for Materials Science CMS, Zewail City of Science and Technology 6th October City 12578 Giza Egypt ielsherbiny@zewailcity.edu.eg.ORCID https://orcid.org/0000-0002-8179-437X
Hoda M MarzoukPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University El-Kasr El-Aini Street 11562 Cairo Egypt martin.nady@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0003-4082-8577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a leading cause of tumor-related mortality worldwide, and there is a critical need for reliable biomarkers that enable early, accurate, and specific diagnosis. Sarcosine, a metabolic byproduct of glycine, has emerged as a potential biomarker for prostate cancer progression, but its low physiological concentration and interference from complex biological matrices make its detection analytically challenging. In this study, a copper-based metal-organic framework supported on graphene oxide (Cu-MOF@GO) was synthesized

Identifiers

PMID42130833
PMCPMC13162336

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.